KPV Research Peptide

Alpha-melanocyte-stimulating hormone is a 13-amino-acid peptide (SYSMEHFRWGKPV) cut from a larger precursor protein, pro-opiomelanocortin. It is best known for driving skin pigmentation, but by the early 1980s physiologist James Lipton and colleagues had found that it also lowers fever in animal models. That raised an obvious question: which part of the molecule carries the message?

Shorter fragments such as alpha-MSH 1–10 did nothing in their fever experiments, so attention turned to the far end of the chain. In 1984 Richards and Lipton showed that the final three residues alone, lysine-proline-valine, reduced fever in rabbits, although with lower potency than the full hormone. Five years later, Hiltz and Lipton reported in The FASEB Journal that the same tripeptide reduced chemically induced ear swelling in mice, in an experiment benchmarked against saline and corticosteroid groups. From that point KPV had a research identity of its own: the smallest piece of alpha-MSH still associated with its anti-inflammatory signalling, without the pigment-producing role of the parent hormone.

The gut is where KPV research has gone deepest. In 2008 a team at the University of Münster tested KPV in two well-established mouse models of colitis, one triggered by dextran sodium sulfate and one by transferring a subset of T cells. Mice given KPV recovered body weight sooner and showed fewer inflammatory cells in the colon wall. Strikingly, the effect held in mice with a non-functional melanocortin-1 receptor, suggesting KPV does not depend entirely on the receptor its parent hormone uses.

The same year, Emory University researchers offered an explanation in Gastroenterology. KPV is small enough to be carried into cells by PepT1, a transporter for di- and tripeptides that is normally found in the small intestine and becomes more abundant in the inflamed colon. Once inside intestinal epithelial cells and T cells, nanomolar concentrations of KPV damped down NF-κB and MAP kinase signalling and lowered pro-inflammatory cytokine output. Later work from the same group packaged KPV into hyaluronic acid-coated nanoparticles to steer it to colonic cells and macrophages in mouse colitis models.

NF-κB is a master switch for inflammatory genes. To do its job, its p65 subunit has to travel into the cell nucleus, carried by transport proteins called importins. A 2012 study from the University of Dundee, working with human bronchial airway cells, found that KPV itself moves into the nucleus and appears to interfere with the site on p65 that importin-α3 recognises. The result was less p65 reaching the nucleus and lower secretion of the chemokines IL-8 and eotaxin.

That intracellular route fits with earlier findings in skin cells. A University of Sheffield team studying human keratinocytes saw no rise in cyclic AMP, the classic messenger of melanocortin receptors, in response to alpha-MSH or KPV, though the peptides did trigger calcium signals under specific conditions. Together these studies make KPV an appealing tool for researchers who want to study NF-κB control by a peptide that does not simply act as a miniature hormone.

Alpha-MSH occurs naturally in barrier organs such as the gut and skin, and that has steered KPV research towards the body’s front lines. In a 2000 study in the Journal of Leukocyte Biology, Cutuli and colleagues reported that both alpha-MSH and KPV inhibited colony formation by Staphylococcus aureus and reduced the viability of the yeast Candida albicans in laboratory tests, including at very low concentrations.

Repair of surface tissue is another strand. In a rabbit model of corneal epithelial wounding, topical KPV was associated with faster re-epithelialisation, an effect that was blocked when nitric oxide production was inhibited. More recently, a rat model of chemotherapy-induced oral mucositis used KPV loaded into a mucosa-adhering hydrogel, with lower IL-1β and TNF-α and higher IL-10 in the healing tissue. Those antimicrobial and barrier findings are why KPV is often considered alongside LL-37, the human cathelicidin peptide studied in innate defence.